Literature DB >> 19908042

Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Hiroyuki Suzuki1, Nobuhito Chikazawa, Takehiko Tasaka, Junji Wada, Akio Yamasaki, Yoshiki Kitaura, Masae Sozaki, Masao Tanaka, Hideya Onishi, Takashi Morisaki, Mitsuo Katano.   

Abstract

The human immune system consists of a balance between immune surveillance against non-self antigens and tolerance of self-antigens. CD8(+) T cells and CD4(+) regulatory T cells (Tregs) are the main players for immune surveillance and tolerance, respectively. We examined immunohistochemically the immunological balance at the tumor site using 94 surgically resected colorectal cancer tissues. Forkhead box P3 (FOXP3)(+) cells were considered to be Tregs in the present study. The number of intratumoral FOXP3(+) cells (itFOXP3(+) cells) was positively correlated with lymph node metastases (P = 0.030). itCD8(+) T/itFOXP3(+) cell ratio negatively correlated with pathological stages (P = 0.048). Next, relationship between the number of itCD8(+) T cells or itFOXP3(+) cells and survival prognosis in 94 patients who underwent a curative resection was analyzed. Only itCD8(+) T/itFOXP3(+) cell ratio positively correlated with disease-free survival (0.023) and overall survival (P = 0.010). Multivariate analysis indicated that itCD8(+) T/itFOXP3(+) cell ratio is an independent prognostic factor (P = 0.035) of overall survival. The number of itFOXP3(+) cells positively correlated with transforming growth factor-beta TGF-beta production at the tumor site (P = 0.020). In conclusion, itCD8(+) T/itFOXP3(+) cell ratio is a predictive marker for both disease-free survival time and overall survival time in patients with colorectal cancer. Importantly, itCD8(+) T/itFOXP3(+) cell ratio may be an independent prognostic factor. And, tumor-producing TGF-beta may contribute to the increased number of itFOXP3(+) cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19908042     DOI: 10.1007/s00262-009-0781-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  77 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  Risk factors. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer.

Authors:  Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

Review 3.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

4.  T-regulatory lymphocytes in peripheral blood of gastric and colorectal cancer patients.

Authors:  Antoni M Szczepanik; Maciej Siedlar; Marek Sierzega; Dominika Goroszeniuk; Karolina Bukowska-Strakova; Antoni Czupryna; Jan Kulig
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

5.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

6.  The clinical implication of tumoral Gal-1 expression in laryngeal squamous cell carcinomas.

Authors:  J Ye; H Liu; Y Hu; G Wan; J Li; Z Wang; P Li; G Zhang; Y Li
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

7.  mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Authors:  Constance Le Goux; Sophie Vacher; Géraldine Pignot; Mathilde Sibony; Nicolas Barry Delongchamps; Benoit Terris; Eliane Piaggio; Marc Zerbib; Diane Damotte; Ivan Bieche
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

8.  Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.

Authors:  Vanessa Deschoolmeester; Marc Baay; Filip Lardon; Patrick Pauwels; Marc Peeters
Journal:  Cancer Microenviron       Date:  2011-05-27

9.  Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer.

Authors:  Shinkyo Yoon; Byung Woog Kang; Su Yeon Park; Hye Jin Kim; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-23       Impact factor: 4.553

Review 10.  Prognostic value of innate and adaptive immunity in colorectal cancer.

Authors:  Fabio Grizzi; Paolo Bianchi; Alberto Malesci; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.